TY - JOUR
T1 - Multianalyte detection of cancer biomarkers in human serum using label-free field effect transistor biosensor
AU - Si, Ke
AU - Cheng, Shanshan
AU - Hideshima, Sho
AU - Kuroiwa, Shigeki
AU - Nakanishi, Takuya
AU - Osaka, Tetsuya
N1 - Funding Information:
The financial support from the National Natural Science Foundation of China (grant number 21705116), the Ministry of Science and Technology of China (grant numbers 2016YFB0401100, 2013CB933403, and 2013CB933504), the National Natural Science Foundation of China (grant numbers 51633006, 91222203, 91233205, and 91433115), and the Chinese Academy of Sciences (grant number XDB12030300) is gratefully acknowledged.
Publisher Copyright:
© 2018 M Y U Scientific Publishing Division. All rights reserved.
PY - 2018
Y1 - 2018
N2 - Recent statistics show that the incidence and mortality of cancer are on the rise. Among all types of cancer, lung cancer and liver cancer are the most prevalent. We have many biomarkers for these two cancers, among which the cytokeratin fragment 21-1 (CYFRA 21-1) and α-fetoprotein (AFP) are the most common and widely used. Among the various detection methods, the field effect transistor (FET) biosensor is one of the most attractive approaches, providing a label-free, fast, and low-cost electrical detection of biomarkers with high specificity and sensitivity. In previous work, we applied biomarkers for a single cancer type. With the detection of CYFRA 21-1 and neuron-specific enolase (NSE), lung cancer was differentiated in the early stages. Compared with the early work, the biomarkers for the two cancer types, CYFRA 21-1 for lung cancer and AFP for liver cancer, were prepared in this work. The detection of CYFRA 21-1 and AFP in human serum was achieved at the same time with the limits of detection of 1 and 10 ng mL−1, while the cut-off values were 4 and 10 ng mL−1. The method featured short analytical time, small sample volume, and low cost. With its good selectivity and appropriate sensitivity, clinical application will become popular in the future.
AB - Recent statistics show that the incidence and mortality of cancer are on the rise. Among all types of cancer, lung cancer and liver cancer are the most prevalent. We have many biomarkers for these two cancers, among which the cytokeratin fragment 21-1 (CYFRA 21-1) and α-fetoprotein (AFP) are the most common and widely used. Among the various detection methods, the field effect transistor (FET) biosensor is one of the most attractive approaches, providing a label-free, fast, and low-cost electrical detection of biomarkers with high specificity and sensitivity. In previous work, we applied biomarkers for a single cancer type. With the detection of CYFRA 21-1 and neuron-specific enolase (NSE), lung cancer was differentiated in the early stages. Compared with the early work, the biomarkers for the two cancer types, CYFRA 21-1 for lung cancer and AFP for liver cancer, were prepared in this work. The detection of CYFRA 21-1 and AFP in human serum was achieved at the same time with the limits of detection of 1 and 10 ng mL−1, while the cut-off values were 4 and 10 ng mL−1. The method featured short analytical time, small sample volume, and low cost. With its good selectivity and appropriate sensitivity, clinical application will become popular in the future.
KW - Biomarker
KW - Concentration-dependent detection
KW - Field effect transistor (FET)
KW - Multianalyte detection
UR - http://www.scopus.com/inward/record.url?scp=85047124017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85047124017&partnerID=8YFLogxK
U2 - 10.18494/SAM.2018.1807
DO - 10.18494/SAM.2018.1807
M3 - Article
AN - SCOPUS:85047124017
SN - 0914-4935
VL - 30
SP - 991
EP - 999
JO - Sensors and Materials
JF - Sensors and Materials
IS - 5
ER -
